Last reviewed · How we verify
NCT05261529: EFINUTRILES
Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus
NA trial testing Extra Virgin Olive Oil (EVOO) in Lupus Erythematosus, Systemic in 90 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Universidad de Granada |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 90 |
| Start date | 3 November 2021 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Extra Virgin Olive Oil (EVOO)
- Physical Exercise Program
Conditions studied
- Lupus Erythematosus, Systemic — all drugs for Lupus Erythematosus, Systemic →
Sponsor
Universidad de Granada — full company profile →
Who can join
Adults 18 to 70, female only, with Lupus Erythematosus, Systemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In addition to the different pharmacological therapies available for the treatment of Systemic Lupus Erythematosus (SLE) as well as for its numerous associated complications (cutaneous, articular, hematological, neuropsychiatric, renal...), it has recently been proposed that 'health-related lifestyles' could have a determining role in balancing numerous organic processes at all levels. In line with this, the benefits of following a healthy dietary pattern such as the Mediterranean Diet and, specifically, the intake of Extra Virgin Olive Oil (EVOO) as well as the realization of regular physical exercise (PE) have been examined in numerous chronic non-communicable diseases such as obesity or cancer. However, in patients with autoimmune diseases, such as SLE, the possible effects of this synergy has not been investigated to date. Having demonstrated both the protective effect of a healthy dietary pattern and that of regular PE on the progression and risks associated with SLE in cross-sectional studies, non-intervention research has been developed that combines both strategies simultaneously, with nutritional supplementation or PE occurring independently. It is hypothesized that supplementation with EVOO in these patients together with PE will produce superior benefits compared to EVOO supplementation alone, showing changes in the phenotype of SLE and other parameters such as levels of chronicity/gravity, biomarkers (oxidative stress, immunological, inflammation), cardiovascular status and body composition.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
EFINUTRILES Study: Integrative Extra Virgin Olive Oil and Multimodal Lifestyle Interventions for Cardiovascular Health and SLE Management.
Gil-Gutiérrez R, Medina-Martínez I, Quesada-Caballero M, de la Hera-Fernández FJ, et al · · 2025 · cited 1× · PMID 40292522 · DOI 10.3390/nu17061076 -
Profiling miRNA in Systemic Lupus Erythematosus Patients Adhering to a Mediterranean Diet: An Interventional Pilot Study
Gil-Gutiérrez R, Medina-Martínez I, Membrive-Jiménez M, Caballero-Mateos A, et al · · 2026
Verify or expand the search:
- PubMed search for NCT05261529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Extra Virgin Olive Oil (EVOO)
Trials testing the same drug.
- NCT06567951 — Extra Virgin Olive Oil Supplementation in Pregnancies With Increased Cholesterol Levels · NA · not yet recruiting
- NCT04077216 — Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients · NA · completed
Other recruiting trials for Lupus Erythematosus, Systemic
Currently open trials in the same condition.
- NCT07424261 — NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care · recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07330245 — Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. · recruiting
- NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
- NCT06881290 — Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus · Phase 1 · recruiting
Other Universidad de Granada trials
Trials by the same sponsor.
- NCT07497698 — Saffron Extract Supplementation and Sleep Quality in Middle-Aged Adults · NA · recruiting
- NCT07528924 — TuJugling: Comparing Two Juggling Learning Methods in College Students · NA · recruiting
- NCT07388134 — Virtual Reality Based High-intensity Interval Training in Chronic Low Back Pain · NA · active not recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT06518200 — Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05261529 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad de Granada
- Last refreshed: 20 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05261529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing